The development that matters most
A personalised vaccine developed by Merck and Moderna stopped skin cancer (melanoma) from returning in what the event record describes as a historic clinical trial.1 The two companies plan to present detailed results at the ESMO cancer conference on October 24, 2026, and to engage with regulators about potential filings.2 That date is still ahead of us, so the full numbers have not yet been published. For readers, that is the most important caveat in this story. The headline result is public. The detail that would let anyone judge how large the benefit is, and for whom, is not.
The same record shows a second regulatory date. Summit's application to the FDA for ivonescimab, based on the HARMONi trial results, has a decision deadline (a PDUFA goal date) of November 14, 2026.3 Together, these two dates give the next six weeks a clear shape.
The second force: AI-designed medicines
The other half of the story is less about a single result and more about method. AstraZeneca's Puja Sapra describes a “lab of the future” in these terms: “Where a self-driving car uses sensors and models to navigate its environment, this system uses AI to make predictions, robotic systems to execute experiments, and instruments to generate data.”4 She argues the approach will produce data at a scale older methods cannot match, and that robotic handling and automated quality checks could shorten early drug development “significantly.”4
Her own account is notably candid about the limits. She writes that “One of the hardest problems in de novo design is predicting whether a computationally generated molecule will be safe in the human body.”4 Her proposed answer is virtual trials using advanced cell systems and micro-scale organ models, which she says have “the potential to generate enhanced biological signals without traditional testing bottlenecks.”4 The word to notice is potential. She also says that “human oversight remains at the heart of this approach.”4 And she names the company's advantage as data: “Data is our differentiator.”4
A note on trust. This article is an essay written by an AstraZeneca executive, and it is a statement of intent rather than a result. Our own source tracking is also unflattering to it. None of the 11 claims we checked from this publication held up under our fidelity testing.4 That figure measures the source in general, not any one sentence above, and the sample is small. Still, it is a reason to read these quotes as the company's ambitions, not as evidence that the technology has worked.
What the money says: Merck's own filings
For a ground-truth check on the company at the centre of the vaccine story, we looked at Merck's SEC filings, which are verified data. They show a company investing more, and holding less cash, than a year earlier.
Capital spending, meaning money spent on plants and equipment, was $4.112 billion in fiscal 2025, up from $3.372 billion in 2024, which is about 22% more.5 In 2023 it was $3.863 billion.5 The first quarter of 2026 was lower than the same quarter a year earlier, at $991 million against $1.328 billion.5 So spending is not rising in a straight line.
Cash tells a bumpier story. Merck held $14.565 billion at the end of 2025, and $18.169 billion at the end of Q3 2025.5 By Q1 2026 it was $5.327 billion, against $8.629 billion a year before.5 At Q2 2026 it was $6.849 billion, against $8.007 billion in Q2 2025.5 In plain terms: cash at Merck's mid-2026 quarter-end was lower than at the same point in 2025. The filings we hold do not say why, so we will not guess.
The cost of making its products, which accountants call cost of revenue, rose too. It was $4.395 billion in Q2 2026 against $3.557 billion in Q2 2025, about 24% more.5 The Q1 comparison is similar, $4.195 billion against $3.419 billion, about 23% more.5 We hold no matching revenue figures in this dossier, so we cannot say whether costs are rising faster or slower than sales. Nor does the dossier tell us whether you hold Merck through an index fund, so we will not claim a weighting.
Evidence the sector is selling more
Novocure, which makes cancer-treatment devices worn by patients, reported second-quarter revenue of $184 million, up 16% on a year earlier, driven by 18% growth in active patients.6 Chief executive Frank Leonard called it “our strongest quarter to date, with record net revenues and active patients on therapy.”6 The company also received a European CE Mark for Optune Pax in pancreatic cancer, with Germany the first market to launch.6
Via News's analysis of the data we hold flags the wider sector mood as bullish, and our narrative notes that Q2 guidance was raised at several oncology-heavy companies, named as Hematology and Oncology, Opzelura and Kiniksa.7 That is our own reading. The documents behind those three guidance upgrades are not in the dossier for this piece, so we cannot verify them here and you should treat them as unconfirmed.
Regulators are moving as well. A European medicines committee recommended Gilead's Trodelvy together with Keytruda as first-line treatment for a form of metastatic breast cancer, called triple-negative, in patients whose tumours carry the PD-L1 marker.8 That is a recommendation, not a final approval. Separately, Telix dosed the first patient in a Phase 3 trial of TLX250-Tx for kidney cancer, which the company describes as the first radiopharmaceutical therapy to reach Phase 3 for that disease.9
The other side: smaller companies need cash
Not everyone in oncology is celebrating. ADC Therapeutics says it “maintains a cash runway into 2028, supporting ongoing regulatory and clinical plans for ZYNLONTA combinations.”10 Yet the same weekly roundup that carries that statement is headlined with job cuts at the company.10 A runway into 2028 is reassuring, and the layoffs are a reminder of what it takes to get there.
Treeline Biosciences is solving the same problem through a deal. Its transaction with Standard BioTools is expected to leave the combined company with more than $900 million at closing.11 Treeline's Josh Bilenker said the extra cash “will help us accelerate the development of our clinical programs.”11 The headline early data for its drug TLN-121 in lymphoma show an overall response rate of 84% and a complete response rate of 32%, with no dose-limiting toxicities observed.11 Those are company-reported Phase 1 figures from a registration-related announcement, so they should be read as early signals. The company says planned updates for TLN-121 and TLN-372 are expected in 2027.11
How much to trust the sources
Via News measures how often the claims from each source have held up when checked. For the press releases above, the figures are 57% for the Novocure and Gilead releases (4,954 claims checked), 31% for the Treeline and Telix releases (2,925 claims), and 45% for the weekly roundup (520 claims).6,8,9,10,11 Those are averages across everything each source has published, not a verdict on any statement here. They do argue for treating company-issued claims about their own drugs as claims, not as findings. The Merck financial figures are different, because they come directly from SEC filings.
What to watch
- October 24, 2026: the detailed intismeran results at ESMO. The question is how large the benefit is, and what Merck and Moderna say about regulatory filings.2
- November 14, 2026: the FDA decision date for ivonescimab.3
- Merck's next filings: whether cash rebuilds and whether capital spending resumes its 2025 pace.5
- 2027: Treeline's planned data updates, the first real test of its early lymphoma numbers.11
The AI-design story has no comparable date. Until a drug designed this way produces trial results, it remains an ambition, however well argued.
